It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Caspase-1 activated in inflammasomes triggers a programmed necrosis called pyroptosis, which is mediated by gasdermin D (GSDMD). However, GSDMD-deficient cells are still susceptible to caspase-1-mediated cell death. Therefore, here, we investigate the mechanism of caspase-1-initiated cell death in GSDMD-deficient cells. Inflammasome stimuli induce apoptosis accompanied by caspase-3 activation in GSDMD-deficient macrophages, which largely relies on caspase-1. Chemical dimerization of caspase-1 induces pyroptosis in GSDMD-sufficient cells, but apoptosis in GSDMD-deficient cells. Caspase-1-induced apoptosis involves the Bid-caspase-9-caspase-3 axis, which can be followed by GSDME-dependent secondary necrosis/pyroptosis. However, Bid ablation does not completely abolish the cell death, suggesting the existence of an additional mechanism. Furthermore, cortical neurons and mast cells exhibit little or low GSDMD expression and undergo apoptosis after oxygen glucose deprivation and nigericin stimulation, respectively, in a caspase-1- and Bid-dependent manner. This study clarifies the molecular mechanism and biological roles of caspase-1-induced apoptosis in GSDMD-low/null cell types.
In inflammasomes, caspase-1 activation leads to pyroptosis mediated by gasdermin D, but cells lacking gasdermin-D still initiate caspase-dependent cell death. Here, Tsuchiya et al. show that these cells undergo Bid- and caspase-3-dependent apoptosis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Kanazawa University, Division of Immunology and Molecular Biology, Cancer Research Institute, Kanazawa, Japan (GRID:grid.9707.9) (ISNI:0000 0001 2308 3329); Kanazawa University, Institute for Frontier Science Initiative (InFiniti), Kanazawa, Japan (GRID:grid.9707.9) (ISNI:0000 0001 2308 3329)
2 Kanazawa University, Division of Immunology and Molecular Biology, Cancer Research Institute, Kanazawa, Japan (GRID:grid.9707.9) (ISNI:0000 0001 2308 3329)
3 Kanazawa University, Department of Neuroanatomy, Graduate School of Medical Sciences, Kanazawa, Japan (GRID:grid.9707.9) (ISNI:0000 0001 2308 3329)
4 Hokkaido University, Institute of Low Temperature Science, Sapporo, Japan (GRID:grid.39158.36) (ISNI:0000 0001 2173 7691)
5 The University of Tokyo, Department of Genetics, Graduate School of Pharmaceutical Sciences, Tokyo, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X)
6 Genetic Strains Research Center, National Institute of Genetics, Mammalian Genetics Laboratory, Shizuoka, Japan (GRID:grid.288127.6) (ISNI:0000 0004 0466 9350)